Status:
RECRUITING
Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma
Lead Sponsor:
Dr Cipto Mangunkusumo General Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
20-60 years
Phase:
PHASE1
Brief Summary
This study represents a phase I clinical trial that utilizes natural killer (NK) cell therapy for patients diagnosed with liver cancer, specifically those classified as Child-Pugh A and falling within...
Eligibility Criteria
Inclusion
- Patients aged 20-60 years old
- Patients with Hepatocellular Carcinoma (HCC) staged as BCLC B and C
- Karnofsky Performance Status (KPS) score ≥ 70
- Expected patient survival of more than three months
- The following parameters are within the normal range:
- Platelet count ≥ 80,000/µL White blood cell count ≥ 3000/µL Neutrophil count ≥ 2000 Hemoglobin ≥ 9 mg/dL International Normalized Ratio (INR) 0.8-1.5 Adequate liver function (bilirubin \< 2, SGOT and SGPT \< 60 U/L) Adequate kidney function (serum creatinine \< 1.3, serum urea \< 10)
Exclusion
- Refusing to participate in the study
- Afflicted by other malignancies, whether non-HCC liver or other malignancies
- Patients are affected by other conditions such as hypertension, severe coronary disease, myelosuppression, respiratory disorders, and acute or chronic infections
- Patients who have previously undergone transplantation and received other stem cell therapies
Key Trial Info
Start Date :
August 29 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT06044506
Start Date
August 29 2022
End Date
December 1 2026
Last Update
September 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cipto Mangunkusumo General Hospital
Jakarta Pusat, Jakarta Special Capital Region, Indonesia, 10430